Stockscreener 앱 받기
1.68
0.59%
-0.01
시간 외 거래:
1.71
0.03
+1.79%
전일 마감가:
$1.69
열려 있는:
$1.67
하루 거래량:
8,828
Relative Volume:
0.46
시가총액:
$67.70M
수익:
$1.88M
순이익/손실:
$-15.57M
주가수익비율:
-4.20
EPS:
-0.4
순현금흐름:
$-50.09M
1주 성능:
-6.15%
1개월 성능:
-0.66%
6개월 성능:
-12.95%
1년 성능:
+12.00%
1일 변동 폭
$1.67
$1.7373
1주일 범위
$1.67
$1.7755
52주 변동 폭
$1.43
$4.00
Beyondspring Inc Stock (BYSI) Company Profile
BYSI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BYSI
Beyondspring Inc
|
1.68 | 67.70M | 1.88M | -15.57M | -50.09M | -0.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.31 | 124.11B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
684.87 | 74.87B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
622.61 | 37.83B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
243.53 | 31.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
111.56 | 26.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Beyondspring Inc Stock (BYSI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-12-02 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2021-12-02 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-12-01 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2021-12-01 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-09-09 | 개시 | Robert W. Baird | Outperform |
| 2021-08-04 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-04-05 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2021-01-11 | 개시 | BofA Securities | Buy |
| 2020-12-29 | 개시 | Evercore ISI | Outperform |
| 2020-02-07 | 개시 | Jefferies | Buy |
| 2020-01-10 | 개시 | Nomura | Buy |
| 2019-12-03 | 개시 | William Blair | Outperform |
| 2019-07-10 | 재확인 | H.C. Wainwright | Buy |
| 2019-04-30 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2018-10-25 | 재확인 | Maxim Group | Buy |
모두보기
Beyondspring Inc 주식(BYSI)의 최신 뉴스
BeyondSpring finalizes significant asset sale By Investing.com - Investing.com South Africa
BeyondSpring finalizes significant asset sale - Investing.com India
BeyondSpring (NASDAQ:BYSI) Stock Price Up 0.6%Time to Buy? - MarketBeat
Cancer Vaccines Market on Track for Major Expansion in - One News Page
Cancer Index takes hit in 2024 amid regulatory setbacks, failures - BioWorld Online
Deal Watch: Novo Nordisk, IMMvention To Partner On Sickle Cell Disease - Citeline News & Insights
SEED Therapeutics Secures FDA Rare Pediatric and Orphan Drug Designations for ST-01156 - MSN
BeyondSpring Inc. Enters into Preferred Share Purchase Agreement with SEED Therapeutics Inc. - Defense World
BeyondSpring sells SEED Therapeutics shares for $35.4M - MSN
SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors - The Manila Times
BeyondSpring sells SEED Therapeutics shares for $35.4M By Investing.com - Investing.com UK
BeyondSpring Announces $35.4 Million Sale of a Portion of - GlobeNewswire
SEED Receives FDA Rare Pediatric Disease and Orphan Drug - GlobeNewswire
BeyondSpring Cashes In $35M Stake as Cancer Drug Shows 89% Disease Control Rate - StockTitan
BeyondSpring (NASDAQ:BYSI) Shares Down 1.4%Here's Why - MarketBeat
Non-Small Cell Lung Cancer Clinical Trial Pipeline Boom as Over 100 Companies Leading the Charge in Research and Development | DelveInsight - The Malaysian Reserve
BeyondSpring Inc. Announces Change in Domestic Filing Status and Disclosure Channels to Disseminate Information - Defense World
BeyondSpring (BYSI) Stock Drops Amidst Biotech Sector Volatility - GuruFocus.com
Germ Cell Tumors Market to Register Significant Growth at a CAGR of 5.5% by 2034 | DelveInsight - The Malaysian Reserve
CTLA-4 Inhibitors Market to Advance at Moderate CAGR During the Study Period (2020-2034) | DelveInsight - The Malaysian Reserve
Retail investors reap multibagger gains by betting on these 29 - Oficjalny Portal Gminy Brzesko
BeyondSpring (NASDAQ:BYSI) Shares Up 4.5%Here's Why - MarketBeat
BeyondSpring (NASDAQ:BYSI) Trading 4.5% Higher – Here’s Why - Defense World
Non-small Cell Lung Cancer Treatment Market 2032: Clinical Trials, Medication, Prevalence, Incidence, Therapies, EMA, PDMA, FDA Approvals, and Companies by DelveInsight - The Globe and Mail
Non-small Cell Lung Cancer Treatment Market 2032: Clinical - openPR
Amazon.com Inc (AMZN-Q) QuotePress Release - The Globe and Mail
NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve
BeyondSpring Presents Updated Efficacy Results from a Phase - GlobeNewswire
BeyondSpring's Lung Cancer Drug Shows 89% Disease Control Rate in Phase 2 Trial | BYSI Stock News - StockTitan
ROS1 Inhibitors Market Booms as Demand for Targeted Cancer Therapies Escalates | DelveInsight - The Malaysian Reserve
BeyondSpring (BYSI) Stock Drops Amid Biotech Sector Volatility - GuruFocus.com
Neutropenia Treatment Market to hit USD 20.8 billion by 2032, says Global Market Insights Inc. - GlobeNewswire
BioWorld Cancer Index continues to decline amid broader market gains - BioWorld Online
Biotech Stocks Facing FDA Decision In November - RTTNews
BYSI (BeyondSpring) Cash From Discontinued Investing Activi - GuruFocus.com
Marshall Wace LLP Buys Shares of 10,538 Poseida Therapeutics, Inc. (NASDAQ:PSTX) - Defense World
Renaissance Technologies LLC Increases Stock Holdings in Mesa Air Group, Inc. (NASDAQ:MESA) - Defense World
CDK4/6 Inhibitors Market to Grow at Healthy Growth Rate by 2034 Owing to Expanded Usage of Approved Blockbuster CDK4/6 Inhibitors in Early-stage Breast Cancer and the Emergence of Newer Players in Other Indications | DelveInsight - PR Newswire UK
Caspase 8 Market Analysis, Trends, Growth, Research And Forecast 2030 - La Funcion mx
G-CSF (Granulocyte Colony Stimulating Factors) Market Size, Analysis, Trends, Overview And Forecast To 2033 - WhaTech
BYSI Sees Quick 5.39% Surge Amid Low Trading Volume - GuruFocus.com
BYSI: BeyondSpring Inc. Stock Surges 7.27% Amid Market Fluctuati - GuruFocus.com
BeyondSpring (BYSI) Stock Surges 6.83% Amid High Volume Trading - GuruFocus.com
Beyondspring Inc (BYSI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.13%
1.23%
자본화:
|
볼륨(24시간):